FY2024 Earnings Forecast for RXRX Issued By Leerink Partnrs

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) – Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for Recursion Pharmaceuticals in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($1.48) per share for the year, down from their prior forecast of ($1.45). The consensus estimate for Recursion Pharmaceuticals’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Recursion Pharmaceuticals’ Q4 2024 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.43) EPS.

Several other research firms have also recently commented on RXRX. KeyCorp lowered their target price on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $7.33 on Friday. The company has a market cap of $2.86 billion, a price-to-earnings ratio of -4.79 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals has a 52 week low of $5.60 and a 52 week high of $15.74. The company has a fifty day simple moving average of $6.90 and a two-hundred day simple moving average of $6.94.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the completion of the sale, the director now directly owns 7,077,560 shares of the company’s stock, valued at $47,561,203.20. The trade was a 0.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,894 shares of company stock worth $279,279. Corporate insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its stake in Recursion Pharmaceuticals by 17.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after acquiring an additional 288,926 shares in the last quarter. FMR LLC grew its holdings in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after purchasing an additional 170,810 shares during the last quarter. Avanza Fonder AB acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $580,000. State Street Corp lifted its holdings in shares of Recursion Pharmaceuticals by 47.1% in the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.